Cargando…

A Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Saroglitazar in Patients With Primary Biliary Cholangitis

Patients with primary biliary cholangitis (PBC) without biochemical response to ursodeoxycholic acid (UDCA) are at increased risk of liver-related mortality. Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with dual PPAR agonistic properties (α/γ). There is a strong...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vuppalanchi, Raj, González-Huezo, Ma Saraí, Payan-Olivas, Ramon, Muñoz-Espinosa, Linda E., Shaikh, Farheen, Pio Cruz-Lopez, Jose L., Parmar, Deven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997082/ https://www.ncbi.nlm.nih.gov/pubmed/33769355 http://dx.doi.org/10.14309/ctg.0000000000000327

Ejemplares similares

Saroglitazar is noninferior to fenofibrate in reducing triglyceride levels in hypertriglyceridemic patients in a randomized clinical trial
por: Rodriguez-Gutierrez, Rene, et al.
Publicado: (2022)

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2023)

New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
por: Kaul, Upendra, et al.
Publicado: (2019)

A Prospective, Multicentre, Open-Label Single-Arm Exploratory Study to Evaluate Efficacy and Safety of Saroglitazar on Hypertriglyceridemia in HIV Associated Lipodystrophy
por: Deshpande, Alka, et al.
Publicado: (2016)

Benefit of glucosyl Hesperidin in patients with primary biliary cholangitis: A multicenter, open-label, randomized control study
por: Moriya, Kei, et al.
Publicado: (2022)

Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis
por: Sarcognato, Samantha, et al.
Publicado: (2021)

A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis
por: Mayo, Marlyn J., et al.
Publicado: (2019)

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)
por: Krishnappa, Manjunath, et al.
Publicado: (2020)

Osteoporosis in primary biliary cholangitis
por: Danford, Christopher J, et al.
Publicado: (2018)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Saroglitazar – A Potential Therapeutic Option in Treating NASH? [Letter]
por: Shuja, Syed Hasan, et al.
Publicado: (2021)

Evaluation of the United Kingdom‐primary biliary cholangitis and global primary biliary cholangitis group prognostic models for primary biliary cholangitis patients treated with ursodeoxycholic acid in the U.S. population
por: Alomari, Mohammad, et al.
Publicado: (2019)

Overlap Syndrome between Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Sundaram, Sridhar, et al.
Publicado: (2018)

Extrahepatic Manifestations of Primary Biliary Cholangitis
por: Chalifoux, Sara L, et al.
Publicado: (2017)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Current understanding of primary biliary cholangitis
por: Tanaka, Atsushi
Publicado: (2021)

Primary biliary cholangitis: pathogenic mechanisms
por: Prieto, Jesús, et al.
Publicado: (2021)

The Role of Epigenetics in Primary Biliary Cholangitis
por: Gerussi, Alessio, et al.
Publicado: (2022)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Timing of biliary decompression for acute cholangitis
por: Yang, Jian, et al.
Publicado: (2023)

Risk Stratification in Primary Biliary Cholangitis
por: Martini, Francesco, et al.
Publicado: (2023)

Predicting Risk in Primary Biliary Cholangitis
por: Cho, Eun Ju
Publicado: (2023)

Follicular T Helper Cell Signatures in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Adam, Leonie, et al.
Publicado: (2018)

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics
por: Park, Ji-Won, et al.
Publicado: (2022)

Saroglitazar for the treatment of hypertrig-lyceridemia in patients with type 2 diabetes: current evidence
por: Sosale, Aravind, et al.
Publicado: (2015)

Biomarkers for primary biliary cholangitis: current perspectives
por: Kouroumalis, Elias, et al.
Publicado: (2018)

Genetic Contribution to the Pathogenesis of Primary Biliary Cholangitis
por: Joshita, Satoru, et al.
Publicado: (2017)

New treatments/targets for primary biliary cholangitis
por: Corpechot, Christophe, et al.
Publicado: (2019)

Primary Biliary Cholangitis-associated Palmar Keratosis
por: Usami, Jun
Publicado: (2021)

Primary Biliary Cholangitis: A Case of Underdiagnosis
por: Garcês Soares, Sofia, et al.
Publicado: (2021)

Update on the Pharmacological Treatment of Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Primary biliary cholangitis: Epidemiology, prognosis, and treatment
por: Trivella, Juan, et al.
Publicado: (2023)

Sequence of events leading to primary biliary cholangitis
por: Lenci, Ilaria, et al.
Publicado: (2023)

External validation of the United Kingdom‐primary biliary cholangitis risk scores of patients with primary biliary cholangitis treated with ursodeoxycholic acid
por: Cheung, Angela C., et al.
Publicado: (2018)

A real‐world observational cohort of patients with primary biliary cholangitis: TARGET‐primary biliary cholangitis study design and rationale
por: Levy, Cynthia, et al.
Publicado: (2018)

Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports
por: Yacoub, Haythem, et al.
Publicado: (2023)

Biliary Fascioliasis in Chronic Calcific Pancreatitis Presenting with Ascending Cholangitis and Biliary Stricture
por: Pattarapuntakul, Tanawat, et al.
Publicado: (2019)

Deciphering the Precise Target for Saroglitazar Associated Antiangiogenic Effect: A Computational Synergistic Approach
por: Dabral, Swarna, et al.
Publicado: (2023)

Clinical application of the GLOBE and United Kingdom‐primary biliary cholangitis risk scores in a trial cohort of patients with primary biliary cholangitis
por: Carbone, Marco, et al.
Publicado: (2018)

A Systematic Review of Patient‐Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
por: Kim, Hannah P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_imtj3ba3lqddilh2m9a7n32e8g